Opendata, web and dolomites

variaTECT SIGNED

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 variaTECT project word cloud

Explore the words cloud of the variaTECT project. It provides you a very rough idea of what is the project "variaTECT" about.

snp    ce    supply    single    plan    double    cognitive    living    aging    cerebrospinal    ivd    variatect    extracted    detection    array    pet    revenues    processed    accurate    data    broad    almost    disorder    score    snpfitrtm    market    cytox    fast    complete    brain    degeneration    diagnostic    mark    stratify    2050    obtain    positron    save    worldwide    drafted    genetic    generate    amyloid    tomography    provides    prevalent    disease    csf    triple    10m    beta    chain    2030    130k    accuracy    saliva    people    85    unresolved    device    polymorphism    plasma    tests    person    solutions    risk    labs    proprietary    upgrade    10k    dna    puncture    probability    dysfunction    platform    alzheimer    individuals    patient    trials    population    multiple    leads    deployment    ad    dementia    strategy    blood    initiated    feasibility    snpfitr    nucleotide    emission    46m    primary    vitro    pieces    fluid    scans    types    snps    figure    collected    subjects    lumbar    capacity    progressively    innovation    software    healthcare    clinical   

Project "variaTECT" data sheet

The following table provides information about the project.

Coordinator
CYTOX LIMITED 

Organization address
address: 53 FOUNTAIN STREET
city: MANCHESTER
postcode: M2 2AN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.cytoxgroup.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOX LIMITED UK (MANCHESTER) coordinator 50˙000.00

Map

 Project objective

Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction and degeneration. The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almost double by 2030 and more than triple by 2050 due to population aging. Current methods for early assessment of AD are based on detection of β-amyloid in the brain Positron Emission Tomography (PET) scans, blood plasma tests or in cerebrospinal fluid (CSF) (via lumbar puncture). However, these solutions present some unresolved issues for broad market deployment. Cytox has developed the variaTECT platform to stratify AD risk in individuals by using a fast, accurate, reliable and cost-effective way to generate specific genetic information. The variaTECT comprises a proprietary 130K single nucleotide polymorphism (SNP) variaTECT array and the proprietary SNPfitRTM software to analyse data generated from the array. DNA extracted from a patient’s blood or saliva sample is collected and analyzed on the variaTECT array. The primary genetic data are then processed by the SNPfitR software, which provides a risk score associated with the probability to develop AD. variaTECT has an 85% accuracy, it can save up to €10k person-year for the healthcare systems and it can generate new revenues (up to €10M) for genetic labs. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, Cytox will upgrade the array design to increase the number of SNPs and the SNPfitR software to stratify subjects into different dementia types. Production capacity will be increased up to 100,000 pieces per year. Multiple clinical trials will be then initiated to obtain CE mark as In-Vitro Diagnostic (IVD) device.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VARIATECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VARIATECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

LOLAS (2019)

Precise and reliable autonomous landing for drones, helicopters and other rotorcraft

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More